Ipilimumab- and nivolumab-induced myocarditis in a patient with metastatic cholangiocarcinoma: a case report

[1] Haslam A(2019)Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs JAMA Netw Open 2 1714-1768

[2] Prasad V(2018)Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline J Clin Oncol 36 1749-1755

[3] Brahmer JR(2016)Fulminant myocarditis with combination immune checkpoint blockade N Engl J Med 375 1755-1764

[4] Lacchetti C(2018)Myocarditis in patients treated with immune checkpoint inhibitors J Am Coll Cardiol 71 854-868

[5] Schneider BJ(2019)Cardiovascular toxicities associated with immune checkpoint inhibitors Cardiovasc Res 115 1-11

[6] Atkins MB(2019)The present and future JACC review topic of the week cardiovascular toxicities of immune checkpoint inhibitors JACC Rev Topic Week 22 1874-1880

[7] Brassil KJ(2020)Cardiac biomarkers in patients with cancer: considerations, clinical implications, and future avenues Curr Oncol Rep 101 316-322

[8] Caterino JM(2015)Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality Heart 362 1475-1487

[9] Johnson DB(2017)Plasma brain natriuretic peptide levels are elevated in patients with cancer PLoS ONE 53 779-792

[10] Balko JM(2003)B-type natriuretic peptide in cardiovascular disease Lancet 59 593-598

[1] Haslam A(2019)Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs JAMA Netw Open 2 1714-1768

[2] Prasad V(2018)Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline J Clin Oncol 36 1749-1755

[3] Brahmer JR(2016)Fulminant myocarditis with combination immune checkpoint blockade N Engl J Med 375 1755-1764

[4] Lacchetti C(2018)Myocarditis in patients treated with immune checkpoint inhibitors J Am Coll Cardiol 71 854-868

[5] Schneider BJ(2019)Cardiovascular toxicities associated with immune checkpoint inhibitors Cardiovasc Res 115 1-11

[6] Atkins MB(2019)The present and future JACC review topic of the week cardiovascular toxicities of immune checkpoint inhibitors JACC Rev Topic Week 22 1874-1880

[7] Brassil KJ(2020)Cardiac biomarkers in patients with cancer: considerations, clinical implications, and future avenues Curr Oncol Rep 101 316-322

[8] Caterino JM(2015)Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality Heart 362 1475-1487

[9] Johnson DB(2017)Plasma brain natriuretic peptide levels are elevated in patients with cancer PLoS ONE 53 779-792

[10] Balko JM(2003)B-type natriuretic peptide in cardiovascular disease Lancet 59 593-598